65,437 trials
Actinic Keratosis
Primary: Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions — 71; 71; 9 Participants
Bone Sarcoma · Femur Fracture · Lymphoma
Primary: Number of Participants With Post-operative Wound Complications — 1; 4; 0; 3 Participants
Cancer of the Esophagus · Adenocarcinoma of the Gastroesophageal Junction · Cancer of the Stomach
Primary: Maximum Tolerated Dose of Vandetanib — 100 milligrams
Oral Mucositis
Primary: Severity of Oral Mucositis — 27; 24; 0; 0 Participants — p=<0.05
Soft Tissue Injuries
Primary: Mean Reduction in BPI-SF Severity — 2.75; 2.44 score on a scale
Smoking Cessation · Cigarette Smoking · Smoking (Tobacco) Addiction
Primary: Change in Number of Cigarettes Smoked Per Day (CPD) — -10.3; -9.0; -7.6 cigarettes per day — p=.55
Stroke · Brain Injuries · Spasticity
Primary: Spastic Hypertonia as Measured by the Ashworth Scale — 2.4; 2.33; 2.36 score on a scale
Cancer of Head and Neck
Primary: Visual Analog Scale (VAS) — 16; 2; 11; 0 score on a scale
Asthma
Primary: Pharmacodynamic Endpoint Post-dose PC20 — 114 mg/mL
Failed Back Surgery Syndrome · Complex Regional Pain Syndrome (CRPS)
Primary: Safety of Ultrahigh Frequency Treatment: Adverse Event (AE) and Serious AE (SAE) — 5 Participants
Epilepsy
Primary: Percentage of Participants Experiencing Any Adverse Events (AEs) Reported Spontaneously by the Subject and/or Caregiver or Observed by Investigator — 59.4 percentage of…
Abortion in First Trimester
Primary: Pain Visual Analog Scale Score (Beads vs Placebo) — 50; 47.5 score on a scale
Single Ventricle · Fontan
Primary: Change in Peak Oxygen Uptake From Baseline Peak Oxygen Uptake — -2.01; -1.01 ml/kg/min
Pancreatic Cancer
Primary: Response Rate as Measured Per RECIST 1.1 Criteria — 12; 2 Participants
Actinic Keratosis
Primary: Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions as Determined by Visual Inspection of the Investigator — 81; 76; 10 Participants